吉西他滨对胰腺癌外周血调节性T细胞影响的研究

寇晓霞; 丁永梅; 黄耀; 袁振刚; 钱其军

doi:10.3969/j.issn.1006-0111.2015.03.018

吉西他滨对胰腺癌外周血调节性T细胞影响的研究

doi: 10.3969/j.issn.1006-0111.2015.03.018

东方肝胆外科医院生物治疗科, 上海 200438

基金项目: 第二军医大学青年启动基金课题(2012QN18)

Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients

Department of Biotherapy, Eastern Hepatobiliary Surgical Hospital, Shanghai 200438, China

摘要: 目的探讨吉西他滨对胰腺癌外周血调节性T细胞的影响,为进一步提高过继免疫治疗的疗效提供依据和参考。方法本研究入选2012年1月至2014年10月收治的32例胰腺癌患者,分为吉西他滨组(吉西他滨+过继免疫治疗)和对照组(单纯过继免疫治疗),观察两组患者治疗前后外周血调节性T细胞水平、化疗不良反应,并对两组患者的生存时间进行分析比较。结果吉西他滨组患者治疗后外周血调节性T细胞水平较治疗前显著降低,与对照组相比亦显著降低,两组比较有统计学差异(P<0.05),吉西他滨组中位生存时间较对照组延长1.3个月(10.0个月与 8.7个月比较)。结论吉西他滨化疗可以显著降低胰腺癌患者外周血调节性T细胞水平,有效调节患者的肿瘤免疫耐受,提高过继免疫治疗的疗效。
- 吉西他滨 /
- 胰腺癌 /
- 调节性T细胞 /
- 过继免疫治疗
Abstract: Objective To investigate the influence of gemcitabine chemotherapy on levels of regulatory T cells(Tregs) in peripheral blood for patients with pancreatic cancer and provide evidence and reference for improving the efficacy of adoptive immunotherapy. Methods 32 patients were enrolled in this study from January 2012 to October 2014, among whom 16 received gemcitabine chemotherapy combined with adoptive immunotherapy(gemcitabine group), the other 16 patients received adoptive immunotherapy only(control group).The level of Tregs in peripheral blood, side effect and overall survival were observed before and after the therapy. Results The number of Tregs in peripheral blood was significantly decreased after gemcitabine chemotherapy, and it was also lower than that of the control group. The overall survival time of the gemcitabine group was 1.3 mo longer than the control group(10.0 mo vs 8.7 mo). Conclusion Therapeutic regimen of gemcitabine can remarkly deplete Tregs in peripheral blood of patients with pancreatic cancer, effectively regulate tumor immune tolerance, and improve the efficacy of adoptive immunotherapy.
- gemcitabine /
- pancreatic cancer /
- regulatory T cells(Tregs) /
- adoptive immunotherapy

[1]	Trouilloud I,Dubreuil O,Boussaha T,et al.Medical treatment pancreatic cancer:new hopes after 10 years of gemcitabine[J].Clin Res Hepatol Gastroenterol,2011,35(5):364-374.
[2]	ShevchenkoI,Karakhanova S, Soltek S,et al.Low-dose gemcetabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer[J].Int J Cancer,2013,133(1):98-107.
[3]	Burris HA,Moore MJ,Andersen J,et al.Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403-2413.
[4]	Hiraoka N,Onozato K,Kosuge T,et al.Prevalence of FOXP3⁺ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions[J].Clin Cancer Res,2006,12:5423-5434.
[5]	Ikemoton T,Yamaguchi T,Morine Y,et al.Clinical roles of increased populations of Foxp3⁺ CD4⁺ T cells in peripheral blood from advanced pancreatic cancer patients[J].Pancreas,2006,33:386-390.
[6]	Shindo Y, Hazama S, Maeda Y,et al.Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcetabine for unresectable pancreatic cancer[J].J Translat Med,2014,12:175.
[7]	Gabitass RF,Annels NE,Stocken DD,et al.Elevated myeloid-derived suppressor cells in pancreatic,esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13[J].Cancer Immunol Immunother,2011,60:1419-1430.
[8]	Ghansah T, Vohra N, Kinney K,et al.Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma[J].Cancer Immunol Immunother,2013,62:1083-1091.
[9]	高强,邱双健,樊嘉.CD4⁺ CD25⁺ FOXP3⁺调节性T细胞在肿瘤免疫逃逸中的作用研究进展[J].中国癌症杂志,2007,17(8):657-662.
[10]	卢晓婷,刘俊田. CD4⁺ CD25⁺调节性T细胞在肿瘤免疫及化疗方面的研究进展[J].中国肿瘤临床,2008,35(11):656-660.
[11]	Homma Y,Tangiguchi K,Nakazawa M,et al.Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer[J].Clini Translat Oncol,2014,16:330-335.
[12]	Bunt SK,Mohr AM,Bailey JM,et al.Rosiglitazone and gemcitabine in combination reduces immune suppression and modulates T populations in pancreatic cancer[J].Cancer Immunol Immunother,2013,62:225-236.

[1]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
[2]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[3]	徐璐璐, 刘爱军. 丹参白术方“异病同治”冠心病、血管性痴呆、特发性膜性肾病的网络药理学作用机制研究 . 药学实践与服务, 2024, 42(12): 1-8. doi: 10.12206/j.issn.2097-2024.202312027
[4]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[5]	修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星. 全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
[6]	姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量. 巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
[7]	杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛. 正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
[8]	顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩. 侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
[9]	丁千雪, 尚圣兰, 余梦辰, 余爱荣. 机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
[10]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
[11]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[12]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[13]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[14]	冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军. 雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
[15]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[16]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
[17]	王鹏, 陈顺, 赵逸, 高守红, 王志鹏. 卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
[18]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[19]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[20]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008

点击查看大图

计量

文章访问数: 3428
HTML全文浏览量: 262
PDF下载量: 395
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

吉西他滨对胰腺癌外周血调节性T细胞影响的研究

doi: 10.3969/j.issn.1006-0111.2015.03.018

Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients

计量

吉西他滨对胰腺癌外周血调节性T细胞影响的研究

doi: 10.3969/j.issn.1006-0111.2015.03.018

东方肝胆外科医院生物治疗科, 上海 200438

English Abstract

Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients

Department of Biotherapy, Eastern Hepatobiliary Surgical Hospital, Shanghai 200438, China

全文HTML

目录

留言板

吉西他滨对胰腺癌外周血调节性T细胞影响的研究

doi: 10.3969/j.issn.1006-0111.2015.03.018

Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients

计量

出版历程

吉西他滨对胰腺癌外周血调节性T细胞影响的研究

doi: 10.3969/j.issn.1006-0111.2015.03.018

东方肝胆外科医院生物治疗科, 上海 200438

English Abstract

Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients

Department of Biotherapy, Eastern Hepatobiliary Surgical Hospital, Shanghai 200438, China

全文HTML

目录